Enliven Therapeutics, Inc. (ELVN)
Health Care ยท Pharmaceutical Preparations
Enliven Therapeutics, Inc. (ELVN) is listed on Nasdaq, where its shares have traded since February 24, 2023. SentiSense covers Enliven Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Richard Fair is its chief executive officer. The company reports 67 employees, and its corporate website is www.enliventherapeutics.com.
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Latest reported results
Enliven Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 201 institutions reported holding ELVN, with 79.9 million shares worth $4.0 billion in aggregate. The largest reported holders were FMR, Orbimed Advisors and Polar Capital Holdings. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on ELVN
- ELVN sentiment: whether news and social coverage of Enliven Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- ELVN ownership: all 201 reporting institutions, plus insider and congressional trades.
- ELVN financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Enliven Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Enliven Therapeutics, Inc. do?
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics.
What sector is ELVN in?
SentiSense classifies Enliven Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ELVN stock trade?
Enliven Therapeutics, Inc. (ELVN) is listed on Nasdaq, where its shares have traded since February 24, 2023.
Who is the CEO of Enliven Therapeutics, Inc.?
Richard Fair is the chief executive officer of Enliven Therapeutics, Inc..